Cagrilintide is a long-acting analog of the hormone amylin, explored primarily in the context of obesity and metabolic disease. It has been studied both as a single agent and in combination with GLP-1 receptor agonists such as semaglutide.

Amylin analogs are of interest because they can complement incretin-based therapies by influencing satiety, gastric emptying, and body-weight regulation through distinct but related pathways.

Cagrilintide is designed to mimic and extend the actions of endogenous amylin, a hormone co-secreted with insulin by pancreatic beta cells. In broad terms, amylin signaling can:

• Slow gastric emptying and modulate postprandial glucose excursions
• Influence satiety centers in the brain and reduce energy intake
• Interact with other hormonal pathways involved in body-weight regulation

When combined with GLP-1 receptor agonists, cagrilintide may offer complementary effects on appetite and metabolism, though the precise contribution of each pathway is still under investigation.

Cagrilintide has been evaluated in clinical trials focused on obesity and related metabolic conditions. Regulatory status and any approved indications, if they emerge, will be highly jurisdiction-specific and may evolve over time.

In many discussions, cagrilintide appears as part of a broader landscape of weight-management strategies that include lifestyle interventions, established therapies, and newer incretin-based or amylin-based agents. Decisions about use belong in a clinical context with careful attention to local regulations.

Reported side effects in studies have generally overlapped with other appetite- and metabolism-focused peptides, including:

• Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation)
• Decreased appetite and early satiety
• Injection-site reactions in some participants

As with other agents affecting weight and metabolism, ongoing observation is important to understand longer-term safety, rare events, and how risks vary across different patient groups.

Cagrilintide has a half-life of approx. 7–8 days, allowing for weekly administration.

This information is based on Phase 2/3 clinical trial designs.

In research, cagrilintide has been administered as a subcutaneous injection, both alone and in fixed or co-administered combinations with GLP-1 receptor agonists. Formulation details, devices, and combination strategies vary by study.

This catalog includes structural entries for single-agent cagrilintide as well as a separate listing for a cagrilintide + semaglutide combination. These listings are organizational and do not represent recommendations about which formulations, if any, are appropriate in a given clinical scenario.

Clinical programs have explored cagrilintide for effects on body weight, cardiometabolic risk factors, and outcomes when combined with GLP-1 receptor agonists. Early results have contributed to the broader conversation around multi-pathway pharmacotherapy for obesity.

As with other emerging agents, the evidence base is still growing. Readers interested in detailed results should consult primary clinical trial publications and, where available, regulatory assessments.

Future FAQs may touch on topics such as how cagrilintide differs from other weight-focused peptides, how combination regimens are being studied, and what kinds of outcomes are being prioritized in trials. Responses will remain high-level and non-prescriptive.